Faculty Bibliography

OBJECTIVE: The purpose of this study was to determine whether the conspicuity of malignant tumors of the pancreas at dual-source dual-energy CT is better with 80-kVp acquisition than with 120-kVp acquisition simulated with a weighted average. MATERIALS AND METHODS: Fifteen patients with pancreatic adenocarcinoma underwent contrast-enhanced dual-source dual-energy CT. The abdominal diameter of all patients was 35 cm or less. Data were reconstructed as a weighted average of the 140- and 80-kVp acquisitions, simulating 120 kVp, and as a pure 80-kVp data set. A region-of-interest cursor was placed within the tumor and the adjacent normal parenchyma, and attenuation differences and contrast-to-noise ratios were calculated for pancreatic tumors at 80 kVp and with the weighted-average acquisition. The 80-kVp and weighted-average images were subjectively compared in terms of lesion conspicuity, image quality, and duct visualization. An exact Wilcoxon's matched pairs signed rank test was used to test whether differences in attenuation, contrast-to-noise ratio, and subjective assessment were greater at 80 kVp. RESULTS: The mean difference in attenuation for each pancreatic tumor and adjacent portion of normal pancreas was 83.27+/-29.56 (SD) HU at 80 kVp and 49.40+/-23.00 HU at weighted-average 120 kVp. Adenocarcinoma attenuation differences were significantly greater at 80 kVp than at 120 kVp (p=0.00006). Contrast-to-noise ratio was significantly higher at 80 kVp than at 120 kVp (p=0.00147). Subjective analysis showed lesion conspicuity (p=0.001) and duct visualization (p=0.0156) were significantly better on the 80-kVp images. CONCLUSION: At portal venous phase dual-source dual-energy CT, the conspicuity of malignant tumors of the pancreas is greater at 80 kVp than with weighted-average acquisition

OBJECTIVE: The purpose of this study was to conduct, using histopathologic examination as the reference standard, a preliminary evaluation of the use of a breath-hold multiecho T2(*)-weighted MRI sequence in the detection and quantification of hepatic iron deposition in patients with liver disease. MATERIALS AND METHODS: The images of 43 patients with liver disease who underwent 1.5-T MRI of the liver that included a multiecho T2(*)-weighted sequence who also underwent concomitant liver biopsy or liver transplantation were assessed. Two independent observers measured hepatic T2(*) by placing regions of interest in the hepatic parenchyma. Hepatic T2(*) values were compared between patients stratified by hepatic iron grade and were correlated with histopathologic iron grade. Receiver operating characteristics analysis was performed to assess the accuracy of images obtained with the hepatic T2(*)-weighted sequence in the diagnosis of iron deposition. RESULTS: Patients with iron deposition had shorter hepatic T2(*) values than did patients without iron deposition (mean T2(*), 17.7 vs 32.3 milliseconds with pooled data from both observers; p < 0.0001). Patients with iron grade 3 or greater had shorter T2(*) values than those with iron grade 2 or less (10.1 vs 20.8 milliseconds; p < 0.0001). There was a strong negative correlation between hepatic T2(*) and histopathologic iron grade (r = -0.849; p < 0.0001). For the prediction of iron grades 1 or greater and 3 or greater, area under the curve, sensitivity, and specificity were 0.968-0.982, 90.5-100%, and 100-97.3% at T2(*) cutoffs of less than 24 and less than 14 milliseconds, respectively. CONCLUSION: Hepatic iron overload in patients with liver disease can be assessed rapidly and accurately with MRI performed with a breath-hold T2(*)-weighted sequence

OBJECTIVE: We review the basics of functional renal imaging and highlight a few clinical applications. CONCLUSION: Techniques such as contrast-enhanced MR renography, diffusion-weighted imaging, and blood oxygen level-dependent MRI have been investigated in animal models and in a few human studies. Functional renal imaging is a rapidly growing field that has the potential to provide new insight into the pathophysiology of renal disease

Dual energy CT (DECT) is a new technique that allows differentiation of materials and tissues based on CT density values derived from two synchronous CT acquisitions at different tube potentials. With the introduction of a new dual source CT system, this technique can now be used routinely in abdominal imaging. Potential clinical applications include evaluation of renal masses, liver lesions, urinary calculi, small bowel, pancreas, and adrenal glands. In CT angiography of abdominal aortic aneurysms, dual energy CT techniques can be used to remove bones from the datasets, and virtual unenhanced images allow differentiation of contrast agent from calcifying thrombus in patients with endovascular stents. This review describes potential applications, practical guidelines, and limitations of dual energy CT in the abdomen

PURPOSE: To evaluate the possible radiation dose reduction facilitated by using dual-energy (DE) multidetector computed tomography (CT) after endovascular repair of abdominal aortic aneurysms (AAAs). MATERIALS AND METHODS: This prospective study was HIPAA compliant and institutional review board approved. Twenty-two patients who previously had undergone endovascular repair of AAAs underwent 24 DE multidetector CT examinations, which were performed with a 64-detector scanner. Initial nonenhanced CT was followed by arterial phase and venous phase acquisitions. Virtual nonenhanced, pure 80-kVp, and weighted-average peak voltage CT data sets were generated from the venous acquisition. Two independent readers interpreted the virtual nonenhanced and DE weighted-average CT data for the presence or absence of endoleaks. These interpretations were compared with the clinical interpretations of the data performed by a different radiologist by using true nonenhanced, arterial phase, and venous phase data. Region-of-interest measurements of the abdominal aorta and of the region of the endoleaks were obtained. Effective radiation dose was calculated. RESULTS: Both independent readers' interpretations of the virtual nonenhanced and weighted-average venous CT data revealed six type II endoleaks. There were no false-positive or false-negative findings. Aortic attenuation during the arterial, 80-kVp venous, and weighted-average data acquisitions were 288, 213, and 150 HU, respectively. The attenuation of the endoleaks was higher during the 80-kVp acquisition (P < .03) than during the arterial phase and weighted-average venous phase acquisitions. The mean effective dose for DE venous phase CT was 11.1 mSv compared with 27.8 mSv for standard triple-phase CT with a single-source configuration. CONCLUSION: Preliminary observations suggest that obtaining DE multidetector CT data by using a single 60-second contrast material-enhanced acquisition may be all that is required for surveillance after endovascular repair of AAA

AIM: To determine the signal characteristics and enhancement patterns of proven pancreatic adenocarcinomas at 1.5 T and to compare these results with contrast enhanced computed tomography (CECT). MATERIALS AND METHODS: Twenty-five patients, mean age 73 years, with proven pancreatic adenocarcinoma were imaged at 1.5 T using in- and opposed-phase, gradient-echo (GRE), T1-weighted sequences, T2 weighting using either a short tau inversion recovery (STIR) or frequency selective, fat-suppressed turbo spin echo (TSE) sequence, and with a three-dimensional (3D), fat-suppressed, GRE T1 sequence before, during the arterial, venous, and equilibrium phases after Gadolinium administration. Fourteen of the 25 patients underwent CECT. Magnetic resonance imaging (MRI) examinations were evaluated by two observers in consensus for size, signal characteristics, and enhancement patterns, and the results were compared with CECT. RESULTS: The mean size of pancreatic adenocarcinomas was 32mm. On unenhanced T1-weighted images, 12 of 25 lesions (48%) were hypointense, 13 (52%) were isointense. On STIR/T2, 11 of 25 (44%) pancreatic adenocarcinomas were hyperintense, 14 (56%) were isointense. All 25 (100%) adenocarcinomas were hypointense during the arterial phase. Twenty (80%) and 17 (68%) remained hypointense in the venous phase and equilibrium phases, respectively. In seven of 14 (50%) cases, the pancreatic mass was iso-attenuating to the pancreatic parenchyma during both the pancreatic and venous phases of CECT. CONCLUSION: The results of the present study showed that all 25 pancreatic adenocarcinomas were hypointense to pancreatic parenchyma during the arterial phase. Moreover, MRI may be useful in patients with a high suspicion of pancreatic carcinoma that is not visualized during CECT

PURPOSE: To retrospectively determine if arterial phase computed tomographic (CT) imaging is necessary for follow-up imaging of patients who have undergone endovascular stent-graft therapy for abdominal aortic aneurysm. MATERIALS AND METHODS: This HIPAA-compliant study was exempt from institutional review board approval; informed patient consent was waived. Eighty-five patients (66 men, 19 women; mean age, 66 years; range, 45-81 years) underwent 110 multidetector CT examinations after endovascular repair of abdominal aortic aneurysms. Nonenhanced CT images were obtained. Intravenous contrast material was then injected at 4 mL/sec, and arterial and venous phase (60 seconds) CT images were obtained. The nonenhanced and venous phase images were evaluated to determine if an endoleak was present. Subsequently, arterial phase images were analyzed. The effective dose was calculated. Ninety-five percent confidence intervals as indicators of how often arterial phase imaging would contribute to the diagnosis of endoleak were determined. RESULTS: Twenty-eight type II endoleaks were detected by using combined nonenhanced and venous phase acquisitions. Twenty-five of the 28 endoleaks were also visualized during the arterial phase. Three type II endoleaks were seen only during the venous phase. The arterial phase images depicted no additional endoleaks. Seventy-eight CT examinations performed in 67 patients revealed no endoleak during the venous phase. The arterial phase images also depicted no endoleaks at these examinations. Thus, for no more than 3.1% of all examinations, there was 95% confidence that arterial phase imaging would depict an endoleak missed at venous phase imaging. Arterial phase imaging contributed to a mean of 36.5% of the effective dose delivered. CONCLUSION: Study results indicate that arterial phase imaging may not be necessary for the routine detection of endoleaks. Radiation exposure can be decreased by eliminating this phase